Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
Annals of Oncology2002Vol. 13(6), pp. 903–909
Citations Over TimeTop 10% of 2002 papers
Frankie A. Holmes, Stephen E. Jones, Joyce O’Shaughnessy, Svetislava J. Vukelja, Timothy George, Michael A. Savin, Donald Richards, John A. Glaspy, Luís Meza, Gary I. Cohen, Mandeep S. Dhami, Daniel R. Budman, James Hackett, Marc-André Brassard, Bingbing Yang, Bertrand C. Liang
Related Papers
- → Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis(2011)248 cited
- → Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group(2009)30 cited
- → Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients(2010)19 cited
- → Pegfilgrastim and filgrastim patterns of use in community oncology practices: Results of the ACCEPT study(2005)3 cited
- → 277MO Filgrastim versus pegfilgrastim as primary prevention for reduction of chemotherapy induced febrile neutropenia in Nepal(2022)1 cited